Snowtox Crystal Serum in China Seoul, January 9, 2026 – LEEYOO LAB announced today the signing of a landmark 1 billion KRW annual contract with a leading Chinese firm for exclusive distribution rights to KAZEN's flagship product, Snowtox Crystal Serum. This deal, facilitated through LEEYOO LAB's full-spectrum consulting—from distributor selection to contract finalization—marks a pivotal step in expanding premium Korean aesthetic skincare into China's dynamic market. ​ Product Spotlight Snowtox Crystal Serum (30ml) leverages patented CDP technology and recombinant botulinum toxin proteins for deep dermal penetration, delivering dual-action whitening and wrinkle reduction. Key ingredients such as niacinamide, adenosine, plankton extract, and allantoin enhance skin brightness, elasticity, and moisture, with clinical trials showing significant wrinkle reduction around eyes, nasolabial folds, and forehead after two weeks. Suitable for all skin types and backed by non-irritation tests, the serum—manufactured by HanSol Life Science and distributed by Kanzen—has proven its appeal in high-demand markets like Japan. Strategic Market Push The partnership targets explosive growth via Chinese wanghong influencer live streams and e-commerce platforms, capitalizing on the product's "topical tox" innovation for baby-smooth skin. LEEYOO LAB's expertise in global B2B negotiations for cosmetics and fillers positions this as a model for regulatory-compliant, high-volume international deals. Industry observers expect robust sales, driven by rising demand for advanced anti-aging solutions in Asia.